Elsevier

Clinical Therapeutics

Volume 28, Issue 3, March 2006, Pages 319-331
Clinical Therapeutics

Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate

https://doi.org/10.1016/j.clinthera.2006.03.003Get rights and content

Abstract

Background:

Inhaled corticosteroids (ICSs) are the most potent anti-inflammatory choice for patients with asthma. Selecting the most appropriate ICS for a patient requires a thorough understanding of the pharmacologic properties of each drug.

Objective:

This review details the pharmacologic properties of ciclesonide (CIC) and fluticasone propionate (FP) and reviews the available data on suppression of the hypothalamic-pituitary-adrenal axis as a measure of systemic exposure and safety profile.

Methods:

Clinical studies and case reports wereidentified through a MEDLINE and EMBASE search of English-language articles. The databases were searched for the years 1990 to April 2005 using the terms ciclesonide, fluticasone, ICS, and adrenal suppression. All studies were clinical trials of pharmacologic properties of the ICSs in humans.

Results:

A total of 1082 articles were identified. CIC and FP are 2 of the most potent ICSs. Both have high receptor-binding affinities (12 times and 18 times that of dexamethasone, respectively), and both may provide enhanced respiratory effects through a prolonged pulmonary residence time. The CIC metered dose inhaler dispenses smaller and more highly respirable particles than FP (1.1–2.1 pm vs 2.8–3.2 μm, respectively). Therefore, a greater percentage of administered CIC is topically deposited in the lungs (52% vs 12% to 13% for FP). CIC is delivered as aninactive parent compound, which is converted to its active metabolite, desisobutyryl-CIC (des-CIC), by esterases in the airways. More than 50% of a dose of CIC is deposited and distributed evenly throughout the lungs of healthy adults; lipid conjugation in the lung also may increase lung residence time. On entering the systemic circulation, both corticosteroids are rapidly cleared by the liver (elimination half-life of 3.5 hours for CIC vs 7.8 hours for FP). However, plasma protein binding is greater with CIC/des-CIC (99%/≈99%) than FP (90%), resulting in reduced amounts of des-CIC (<I%) versus FP (10%) circulating free in the plasma. Although studies of low or medium doses of FP have produced conflicting results, high doses of FP (>660 pg/d) may result in adrenal suppression. CIC has not been reported to produce any significant adrenal suppression throughout its studied dose range (up to 1280 μ/d).

Conclusions:

A review of the literature suggests that CIC, as compared with FP, achieves greater pulmonary deposition, causes fewer adverse oropharyngeal effects, deposits less biologically active drug in the systemic circulation, and has less potential for adrenal suppression.

References (101)

  • KempJ.P. et al.

    Potential effects of fluticasone propionate on bone mineral density in patients with asthma: A 2-year randomized, double-blind, placebocontrolledtrial

  • MitchellP. et al.

    Inhaled corticosteroids, family history, and risk of glaucoma

    Ophthalmology

    (1999)
  • OpatowskyI. et al.

    Intraocular pressure elevation associated with inhalation and nasal corticosteroids

    Ophthalmology

    (1995)
  • ToogoodJ.H. et al.

    Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment ofasthma

    J Allery Clin Immunol

    (1993)
  • SimonsF.E. et al.

    Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids

    Lancet

    (1993)
  • StormsW.W. et al.

    Clinical adverse effects of inhaled corticosteroids: Results of a questionnaire survey of asthma specialists

    Ann Allergy Asthma Immunol

    (1998)
  • AsmusM.J. et al.

    In vitro deposition of fluticasone aerosol from a metered-dose inhaler with and without two common valved holding chambers

    Ann Allergy Asthma Immunol.

    (2002)
  • CrippsA. et al.

    Pharmaceutical transition to non-CFC pressurized metered dose inhalers

    Respir Med.

    (2000)
  • LeachC.L. et al.

    Lung deposition of hydrofluoroalkane-134a beclo methasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbonbeclomethasone: A cross-over study in healthy volunteers

    Chest

    (2002)
  • SzeflerS.J. et al.

    Significant variability in response to inhaled corticosteroids for persistent asthma

    J Allergy Clin Immunol.

    (2002)
  • CasaleT.B. et al.

    Suppression of hypothalamicpituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients

    Ann Allergy Asthma Immunol.

    (2001)
  • FowlerS.J. et al.

    Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate

    Chest

    (2002)
  • ChervinskyP. et al.

    Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma

    J Allergy Clin Immunol

    (1994)
  • WeinerP. et al.

    Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate

    Chest

    (1999)
  • WongJ. et al.

    Estimation of the dose of fluticasone propionate inhaled by infants after bronchiolitis: Effect on urinary cortisol excretion

    J Allergy Clin Immunol

    (2002)
  • PearlmanD.S. et al.

    Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma

    J Allergy Clin Immunol.

    (2005)
  • LipworthB.J. et al.

    Effect of ciclesonide and fluticasone on hypothalamic-pituitaryadrenal axis function in adults with mild-to-moderate persistent asthma

    Ann Allergy Asthma Immunol

    (2005)
  • NaveR. et al.

    Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide

    Pulm Pharmacol Ther.

    (2005)
  • DeromE. et al.

    Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′ monophosphate in asthmatic patients

    Pulm Pharmacol Ther.

    (2005)
  • National Asthma Education and Prevention Program

    Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma

    (1997)
  • National Institutes of Health, National Heart, Lung, and Blood Institute

    Global Initiative for Asthma

  • BarnesP.J. et al.

    Efficacy and safety of inhaled corticosteroids. New developments

    Am J Respir Crit Care Med.

    (1998)
  • ToogoodJ.H.

    Inhaled steroid asthma treatment: ‘Primum non nocere’

    Can Respir J.

    (1998)
  • BarnesP.J.

    Inhaled glucocorticoids for asthma

    N Engl J Med.

    (1995)
  • WilliamsonI.J. et al.

    Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations

    Eur Respir J.

    (1995)
  • LipworthB.J. et al.

    Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids

    Thorax

    (1997)
  • WolthersO.D. et al.

    Measures of hypothalamicpituitary-ad renal function in patients with asthma treated with inhaled glucocorticoids: Clinical and researchimplications

    J Asthma.

    (1999)
  • PescollderunggL. et al.

    Systemic activity of inhaled corticosteroid treatment in asthmatic children: Corticotrophin releasing hormone test

    Thorax

    (2003)
  • NelsonH.S. et al.

    A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids

    J Clin Pharmacol.

    (2002)
  • ThalerL.M. et al.

    The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency

    J Clin Endocrinol Metab.

    (1998)
  • AbduT.A. et al.

    Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance testfor assessment of the hypothalamopituitary-adrenal axis in patients with pituitary disease

    J Clin Endocrinol Metab.

    (1999)
  • BroideJ. et al.

    Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids

    J Clin Endocrinol Metab.

    (1995)
  • OrthD.N. et al.

    The adrenal cortex

  • ToddG.R. et al.

    Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom

    Arch Dis Child.

    (2002)
  • DrakeA.J. et al.

    Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate

    BMJ

    (2002)
  • DunlopK.A. et al.

    Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid

    Pediatr Pulmonol.

    (2002)
  • AliN.J. et al.

    Bone turnover during high dose inhaled corticosteroid treatment

    Thorax

    (1991)
  • SivriA. et al.

    Effect of the longterm use of inhaled corticosteroids on bone mineral density in asthmatic women

    Respirology.

    (2001)
  • IsraelE. et al.

    Effects of inhaled glucocorticoids on bone density in premenopausal women

    N Engl J Med.

    (2001)
  • SharmaP.K. et al.

    Effect of inhaled steroids on bone mineral density: A meta analysis

    J Clin Pharmacol.

    (2003)
  • Cited by (0)

    View full text